In re Effexor XR Antitrust Litigation

Berger Montague currently serves as a member of the Interim Class Counsel Executive Committee on behalf of a proposed class of direct purchasers of brand or generic versions of Effexor XR from Wyeth (Wyeth LLC, Wyeth Pharmaceuticals, Inc., Wyeth-Whitehall Pharmaceuticals LLC, and Wyeth Pharmaceuticals Company) or Teva (Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries Ltd.) (Wyeth and Teva are collectively referred to as “Defendants”) in this antitrust class action alleging that Defendants unlawfully delayed the entry of less expensive generic Effexor XR (generic name: venlafaxine hydrochloride extended-release) through an unlawful “reverse payment” agreement.

The case is currently pending in the United States District Court for the District of New Jersey and is captioned In re Effexor XR Antitrust Litigation, No. 3:11-cv-05479 (D.N.J.).

The Class settled with Wyeth for $39 million, and litigation against Teva continues.

Berger Montague is one of the nation’s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, DC, and Wilmington, DE.